Allergy Diagnostics and Therapeutics Market Demand Is Shifting Toward Confirmatory Testing and Targeted Treatment
Allergy diagnostics and therapeutics covers the testing systems, consumables, assays, prescription drugs, biologics, immunotherapies, emergency allergy treatments, and clinical services used to identify and manage allergic conditions such as allergic rhinitis, asthma-related allergy, eczema, food allergy, drug allergy, insect-sting allergy, and anaphylaxis risk. The global Allergy Diagnostics and Therapeutics market is estimated at around USD 39.75 billion in 2026 and is projected to reach nearly USD 84.59 billion by 2035, reflecting a CAGR of about 8.76% during 2026–2035. Demand is being driven by a high diagnosed allergy base in North America and Europe, wider use of specific IgE and component-resolved diagnostics, more biologic treatment options for food allergy and allergic asthma, and stronger clinical preference for separating true IgE-mediated allergy from intolerance, sensitivity, or non-allergic respiratory disease.
Diagnosed Allergy Burden Is Expanding the Testing and Treatment Pool
The strongest demand source for allergy diagnostics and therapeutics is not only new allergy incidence but the large pool of patients moving from symptomatic self-management to physician-guided diagnosis. In the United States, 2024 health survey data showed that 31.7% of adults had at least one diagnosed seasonal allergy, eczema, or food allergy. Seasonal allergy alone affected 25.2% of adults, while diagnosed food allergy affected 6.7%. Among children, 20.6% had seasonal allergy, 12.7% had eczema, and 5.3% had food allergy. This creates repeat demand for allergist consultations, skin-prick testing, serum IgE testing, epinephrine prescriptions, antihistamines, corticosteroids, leukotriene modifiers, biologics, and immunotherapy follow-up.
Europe is another high-intensity market because allergy is already a mass chronic-disease category rather than a niche specialist condition. Around 150 million Europeans live with chronic allergic diseases, and around 7 million Europeans have food allergies. The treatment burden is also economic: poorly controlled allergy and asthma are linked with avoidable productivity loss and higher medication use. This is why demand in Europe is stronger in countries with dense specialist networks, reimbursement access, and established laboratory infrastructure, including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, and Nordic countries.
Diagnostics Segment Is Moving from Screening to Precision Allergy Identification
Within allergy diagnostics, specific IgE blood testing, skin-prick testing, patch testing, food challenge testing, and component-resolved diagnostics serve different clinical needs. Skin-prick testing remains widely used in clinics because it is low-cost, fast, and suitable for common inhalant and food allergens. However, in-vitro allergy diagnostics is gaining share in hospital laboratories and reference labs because it supports quantitative measurement, standardized reporting, pediatric testing where skin testing may be difficult, and risk stratification before immunotherapy or biologic use.
The higher-value part of the diagnostics segment is component-resolved diagnostics. Instead of only identifying sensitivity to a whole allergen extract, component testing helps distinguish primary allergy from cross-reactivity. This matters in peanut, tree nut, pollen-food syndrome, venom allergy, and severe food allergy risk assessment. Thermo Fisher Scientific’s ImmunoCAP portfolio, for example, includes more than 550 whole allergens, allergen mixes, and allergen component tests, with a stated set of 72 FDA-cleared ImmunoCAP allergen components. This type of portfolio depth strengthens the laboratory-based segment because hospitals and commercial labs can process broader panels while improving clinical interpretation.
Therapeutics Remain Larger Because Treatment Is Recurring and Risk-Based
Therapeutics is stronger than diagnostics in revenue terms because allergy treatment is recurring, risk-linked, and often chronic. Antihistamines and corticosteroids dominate volume because allergic rhinitis, eczema, and mild respiratory allergy require frequent symptom control. Immunotherapy, including subcutaneous immunotherapy and sublingual immunotherapy, generates longer treatment cycles because patients commonly require multi-year regimens. Biologics are smaller in patient count but much higher in spending per treated patient, especially for severe allergic asthma, chronic urticaria, atopic dermatitis overlap, and food allergy risk reduction.
Recent approvals are changing treatment economics. In February 2024, the U.S. FDA approved Xolair, or omalizumab, for IgE-mediated food allergy in adults and children aged one year and older to reduce allergic reactions after accidental exposure to one or more foods. This shifted food allergy therapy beyond avoidance-only management and peanut-specific oral immunotherapy. In August 2024, the FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kg. The product adds a needle-free option in a category historically led by epinephrine auto-injectors, which may improve carrying behavior and rapid-use compliance among children and needle-averse patients.
Pricing, Access, and Clinical Capacity Still Limit Market Conversion
The market is not growing evenly across all patient groups. Basic antihistamines are highly accessible, but specialist diagnosis, component testing, biologic therapy, and immunotherapy depend on reimbursement, allergist availability, laboratory access, and patient adherence. Food challenge testing requires trained clinical supervision, which limits throughput. Immunotherapy requires repeated dosing and follow-up, making dropout a commercial and clinical challenge. Biologics can expand revenue quickly but remain payer-controlled because treatment costs are high and eligibility is evidence-based.
Supply is concentrated around established diagnostic and pharmaceutical companies. Diagnostics demand depends on instrument placement, reagent menus, quality-control systems, and lab contracts, while therapeutics demand depends on regulatory approvals, payer coverage, physician confidence, and pharmacy distribution. As a result, the Allergy Diagnostics and Therapeutics market is strongest where clinical pathways connect primary care, allergists, laboratories, emergency treatment access, and reimbursed long-term therapy. The main challenge through 2035 will be converting the very large allergy prevalence base into confirmed diagnosis and sustained treatment rather than episodic over-the-counter symptom management.
Regional Allergy Diagnostics and Therapeutics Demand Is Led by Testing Access, Specialist Density, and Reimbursement
Regional behavior in the Allergy Diagnostics and Therapeutics market is shaped less by physical production capacity and more by clinical access, laboratory infrastructure, prescription coverage, allergist availability, and emergency-treatment distribution. North America remains the most monetized market because diagnosed allergy rates are high, commercial insurance supports higher-value biologics, and reference laboratories have strong penetration of specific IgE testing. The United States is the central demand country, with nearly one-third of adults and children reporting diagnosed seasonal allergy, eczema, or food allergy in 2024. This creates steady utilization across primary care, allergy clinics, pediatric practices, emergency departments, retail pharmacies, and commercial labs.
The U.S. market is stronger than most regions in biologic adoption because allergy overlaps with asthma, atopic dermatitis, chronic urticaria, and food allergy management. FDA approval of Xolair for IgE-mediated food allergy in February 2024 widened the addressable treatment base beyond asthma and chronic spontaneous urticaria. FDA approval of neffy epinephrine nasal spray in August 2024 also changed emergency allergy treatment access by adding a needle-free prescription option for Type I allergic reactions, including anaphylaxis. This matters commercially because emergency allergy products are replacement-driven: patients often need two-device packs, school backups, travel packs, and periodic replacement before expiry.
Europe Is a High-Diagnosis Region but Pricing Is More Controlled
Europe has one of the largest treated allergy populations, supported by dense public health systems, specialist networks, and established immunotherapy use. Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Denmark, Sweden, and Switzerland are key demand countries. The region’s demand base is broad: allergic rhinitis, asthma-linked allergy, food allergy, venom allergy, and atopic dermatitis all contribute to testing and treatment use. Around 150 million Europeans are affected by chronic allergic diseases, and around 7 million have food allergies, creating demand for both early diagnosis and long-term disease management.
Europe differs from the United States in pricing behavior. Diagnostic test reimbursement, national formularies, tendering, and prescription rules keep average selling prices more controlled. However, Europe is structurally strong in allergen immunotherapy. Denmark-based ALK and Switzerland-headquartered Stallergenes Greer have deep immunotherapy portfolios covering sublingual tablets, subcutaneous immunotherapy, drops, venom allergy products, and anaphylaxis-related products. Europe also has higher acceptance of allergy immunotherapy as a disease-modifying therapy, especially in pollen, grass, house dust mite, and venom allergy.
Asia Pacific Demand Is Expanding Through Urban Allergy Burden and Lab Penetration
Asia Pacific is a mixed market. Japan has one of the clearest seasonal allergy demand structures because cedar pollen allergy affects a very large part of the population. Japan’s Ministry of Agriculture, Forestry and Fisheries reported that about 40% of the population suffers from cedar pollen allergy every spring, and the government strengthened pollen-reduction measures in 2024. This creates recurring demand for antihistamines, nasal corticosteroids, allergist visits, immunotherapy, and preventive treatment before pollen season.
China and India represent high-volume but unevenly monetized markets. Demand is driven by urbanization, air pollution exposure, respiratory allergy, pediatric allergy, and expanding private diagnostics. China’s allergy diagnostics demand is concentrated in Tier-1 and Tier-2 cities where hospitals and independent clinical laboratories have the required immunoassay systems. India is more price-sensitive, with allergy testing often concentrated in private hospitals, large pathology chains, pulmonology clinics, ENT practices, and pediatric centers. A 2025 multicenter Indian clinic-based study across 19 states and union territories found allergic rhinitis in 53.7% of patients visiting doctors with nasal symptoms, showing that diagnostic demand is significant but still under-converted into formal testing.
Supply Setup Depends on Reagent Menus, Lab Platforms, and Prescription Distribution
Supply in this market is split into three layers. The first is diagnostics, where companies supply immunoassay instruments, allergen panels, reagents, calibrators, controls, and software-supported reporting. The second is therapeutics, where pharmaceutical and biologic suppliers distribute prescription drugs through wholesalers, hospital pharmacies, specialty pharmacies, and retail chains. The third is clinical service delivery, where allergists, ENT doctors, pulmonologists, pediatricians, dermatologists, emergency physicians, and laboratory networks convert patient symptoms into diagnosis and treatment.
Import-export dependency is relevant mainly for diagnostic reagents, immunotherapy extracts, epinephrine products, and biologics. Many emerging markets depend on imported diagnostic platforms, branded immunotherapy products, and biologics from Europe or the United States. Local manufacturing is more common for generic antihistamines, nasal sprays, corticosteroids, and some emergency allergy products, but high-specificity component diagnostics and biologics remain concentrated among global suppliers.
Key segmentation behavior is visible across product and customer groups:
- Diagnostics: Skin-prick testing remains strong in specialist clinics due to low cost and quick results, while serum IgE and component-resolved diagnostics are stronger in hospitals and reference labs.
- Therapeutics: Antihistamines and corticosteroids lead in volume; biologics and immunotherapy lead in value per patient.
- Applications: Allergic rhinitis has the broadest patient base; food allergy and anaphylaxis create higher-risk clinical pathways; asthma-linked allergy supports biologic adoption.
- Customer groups: Hospitals, specialty allergy clinics, diagnostic laboratories, pediatric practices, ENT clinics, pulmonology centers, and retail pharmacies are the main buyers or service points.
- Regions: North America leads in biologic monetization, Europe leads in immunotherapy depth, Japan leads in seasonal pollen-driven demand intensity, and China and India lead in underpenetrated patient volume.
Procurement behavior is becoming more evidence-driven. Laboratories prefer platforms with large allergen menus, automation compatibility, reproducible results, and clinician-recognized interpretation. Payers and hospitals are also pushing for confirmatory diagnosis before high-cost therapies. This supports long-term growth for in-vitro diagnostics, but cost pressure remains high in Asia, Latin America, the Middle East, and parts of Eastern Europe.
Competitive Positioning Depends on Test Menu Depth, Biologic Strength, and Clinical Channel Access
The Allergy Diagnostics and Therapeutics market has a mixed competitive structure. Diagnostics is concentrated around companies with validated immunoassay platforms, broad allergen panels, and laboratory relationships. Therapeutics is broader, covering OTC drugs, prescription allergy drugs, immunotherapy specialists, biologic developers, and emergency anaphylaxis brands. Exact market share is not consistently disclosed across combined diagnostics and therapeutics, so competitive position is better assessed through portfolio strength, regulatory approvals, distribution reach, clinical familiarity, and reimbursement access.
Thermo Fisher Scientific is one of the strongest suppliers in in-vitro allergy diagnostics through its ImmunoCAP allergy testing portfolio. Its strength comes from allergen-menu depth, component-resolved diagnostics, and long-standing placement in hospital and reference laboratories. The ImmunoCAP portfolio includes more than 500 whole allergens and allergen mixes, with component testing used to support risk assessment and more specific diagnosis. This gives Thermo Fisher an installed-base advantage because laboratories using its platforms can expand test menus without changing the core diagnostic workflow.
Siemens Healthineers also participates through immunoassay systems used in clinical laboratories, while EUROIMMUN, a PerkinElmer/Revvity business, is active in allergy and autoimmune diagnostics with immunoblot and assay-based portfolios. HYCOR Biomedical, Omega Diagnostics, R-Biopharm, bioMérieux, and several regional suppliers compete in selected assay, reagent, or lab-service niches. The diagnostics side is not only a product market; it is also a service ecosystem where laboratories require training, instrument uptime, reagent continuity, external quality assessment, and clinician confidence.
Immunotherapy Specialists Hold Strong Positions in Disease-Modifying Allergy Treatment
Allergen immunotherapy is led by specialist companies because product quality, allergen standardization, dosing formats, clinical data, and physician trust matter heavily. ALK is among the leading global allergy immunotherapy suppliers, with products across sublingual tablets, subcutaneous immunotherapy, drops, and anaphylaxis-related products. In its 2025 annual reporting, ALK stated that revenue grew 15% to DKK 6.31 billion, with tablet sales rising 17% to DKK 3.34 billion and SCIT/SLIT drops increasing 5% to DKK 2.15 billion. This indicates that tablet-based immunotherapy is gaining faster than traditional injection and drop formats because it improves convenience and expands prescriber adoption.
Stallergenes Greer is another important immunotherapy supplier, with a portfolio across respiratory allergy, venom allergy, sublingual products, and allergen extracts. Its competitive position is strongest in Europe and selected international markets where allergen immunotherapy is integrated into specialist practice. Regional immunotherapy competition depends heavily on regulatory acceptance, local allergen relevance, cold-chain or controlled distribution needs, and physician training.
Biologic Suppliers Are Reshaping High-Value Allergy Therapeutics
Biologic treatment is the highest-value segment in allergy therapeutics because eligible patients often have severe, recurrent, or multi-system allergic disease. Sanofi and Regeneron hold a leading position through Dupixent, which is used across several type-2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and chronic spontaneous urticaria in some approved markets. Sanofi reported strong Dupixent momentum in 2024 and 2025, with sales growth supported by multiple indications and broad specialist adoption.
Roche, Novartis, and Genentech are important through Xolair, which gained additional relevance after FDA approval for IgE-mediated food allergy in February 2024. The approval made Xolair the first FDA-approved medication to reduce allergic reactions to more than one food after accidental exposure. This changes the competitive structure in food allergy, where treatment historically centered on avoidance, epinephrine readiness, and limited oral immunotherapy options.
ARS Pharmaceuticals is important in emergency allergy treatment through neffy. The August 2024 FDA approval created the first nasal-spray epinephrine option for anaphylaxis in eligible adults and children. ALK’s in-licensing of neffy also shows how immunotherapy companies are extending into adjacent allergy emergency-care products. Viatris remains relevant in epinephrine auto-injectors through EpiPen, while generics and authorized generics continue to influence pricing pressure.
Pricing behavior varies sharply by segment. OTC antihistamines are competitive and volume-led, with private-label pressure in pharmacies. Prescription nasal sprays and leukotriene modifiers face generic competition. Immunotherapy pricing depends on treatment duration, allergen type, dosing format, and physician administration. Biologics face the strongest payer scrutiny because annual treatment costs are high and prior authorization is common. Diagnostics pricing is shaped by reimbursement codes, lab contracts, allergen panel size, and reagent lock-in with installed instruments.
Recent developments shaping competition include:
- February 2024, United States: FDA approved Xolair for IgE-mediated food allergy in adults and children aged one year and older, expanding biologic use into food allergy risk reduction.
- August 2024, United States: FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for Type I allergic reactions, including anaphylaxis, creating a needle-free emergency allergy treatment category.
- April 2024, France/global: Sanofi reported Dupixent Q1 sales of EUR 2.84 billion, up 24.9%, showing continued demand for type-2 inflammation therapies.
- February 2025, Denmark/global: ALK reported 2024 sales growth of 15%, supported by allergy tablets, SCIT/SLIT drops, and anaphylaxis products.
- 2024, Japan: The Government of Japan strengthened measures to reduce cedar pollen dispersal, reflecting the scale of hay fever burden and sustaining demand for seasonal allergy management.
- 2025, India: A multicenter clinic study across 19 states and union territories found allergic rhinitis in 53.7% of nasal-symptom patients, supporting stronger demand for formal diagnosis in private healthcare channels.
Statistical Meta Description
Allergy Diagnostics and Therapeutics market demand is rising through higher diagnosed allergy prevalence, wider use of specific IgE and component-resolved testing, biologic approvals, immunotherapy adoption, and emergency anaphylaxis treatment expansion. The market is estimated at USD 39.75 billion in 2026 and projected to reach USD 84.59 billion by 2035 at an 8.76% CAGR. North America leads value generation through biologics and advanced diagnostics, Europe remains strong in immunotherapy, while Asia Pacific growth is supported by pollen allergy, urban respiratory disease, and private laboratory expansion. Key suppliers include Thermo Fisher Scientific, ALK, Stallergenes Greer, Sanofi, Regeneron, Roche, Novartis, ARS Pharmaceuticals, and Viatris.
About Datavagyanik
Datavagyanik is a business intelligence firm with clients worldwide. We provide the right knowledge and advice to business organizations and help them to grow and excel. We specialize in areas such as Pharmaceutical, Healthcare, Manufacturing, Consumer Goods, Materials & Chemicals, and others. We specialize in market sizing, forecasting, supply chain analysis, supplier intelligence, import-export insights, market trend analysis, and competitive intelligence.
Contact us:
Atul B (Sales Head)
Phone: +1 551 226 6002
Website: https://datavagyanik.com/
Email: sales@datavagyanik.com
